As noted by Henao and Craig [9], AAT replacement therapy increases AAT levels, reducing the damage caused by neutrophil elastase to the lung tissue, while IVIG therapy can provide benefits beyond the correction of immunodeficiency, including the modulation of underlying autoimmunity and potential protective effects in patients with associated malignancy. This evidence concerns the gene SERPINA1 and immunodeficiency disease.